Table 1. Clinical and pathological patient characteristics.

	All patients			Matched patients
	Incontinent	Continent	P value	Incontinent	Continent	P value
n	47	68		34	34
Ileal conduit / cutaneous ureterostomy, n =	17 / 30			14 / 20
Median age*, years (IQR)	67 (64–76)	68 (58–71)	0.018	66 (61–72)	68 (58–71)	0.437
Gender* (M/F), n =	39 / 8	47 / 21	0.126	26 / 8	27 / 7	0.770
Mean ECOG-PS* (±SD)	0.0±0.2	0.0±0.0	0.160	0.1±0.2	0.0±0.0	0.156
Median follow-up, months (IQR)	72 (53–112)	97 (70–125)	0.093	73 (54–98)	101 (74–126)	0.139
Neoadjuvant chemotherapy, n =	18 (38%)	35 (51%)	0.186	13 (38%)	16 (47%)	0.624
TNM classification
cT* (±SD)	2.4±0.9	2.3±0.8	0.259	2.4±0.9	2.2±0.8	0.212
pT (±SD)	2.1±1.2	1.4±1.2	0.001	2.0±1.2	1.3±1.1	0.009
pN+, n =	7 (15%)	1 (1.5%)	0.008	6 (18%)	1 (3%)	0.105
Cardiovascular disease*, n =	3 (6%)	9 (13%)	0.354	2 (6%)	1 (3%)	0.555
Hypertension*, n =	21 (45%)	27 (40%)	0.701	14 (41%)	14 (41%)	1.000
Diabetes*, n =	5 (11%)	8 (12%)	1.000	5 (15%)	6 (18%)	0.742
Median blood loss, kg (IQR)	1.5 (0.9–2.3)	1.3 (0.9–2.0)	0.131	1.4 (1.1–1.9)	1.3 (0.9–1.6)	0.153
Median operative duration, hours (IQR)	4.7 (4.0–6.3)	5.0 (4.4–6.2)	0.897	4.8 (4.0–6.2)	4.8 (4.5–6.0)	0.789
Postoperative Complications, n =	18 (38%)	26 (38%)	1.000	19 (56%)	19 (56%)	1.000
Postoperative hydronephrosis (> G1), n =	16 (34%)	5 (7%)	<0.001	12 (35%)	4 (12%)	0.043
Ureteral stent, n =	23 (49%)	0 (0%)	<0.001	15 (44%)	0 (0%)	<0.001
Ileal conduit, stent (+)	2 (12%)			1 (7%)
Cutaneous ureterostomy, stent (+)	21 (70%)			14 (70%)
Recurrence, n =	15 (32%)	6 (9%)	0.003	10 (29%)	2 (6%)	0.023
Chemotherapy for recurrent disease, n =	14 (30%)	4 (6%)	0.001	9 (27%)	1 (2.9%)	<0.001
Median cycle (IQR)	4 (2–6)	4 (1–5)	0.413	6 (3–14)	3 (1–4)	0.029

* applied for propensity score-matching

SD, standard deviation; IQR, interquartile range.